Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Propeller Health

- PMLiVE

Novartis bribery probe in Greece ‘could affect general election’

The pharma giant allegedly gave “bundles of cash” to civil servants, doctors and politicians

- PMLiVE

ICER says price of Amgen/Novartis’ Aimovig is OK – if used last-line

Recommends the drug should only be used in patients who have exhausted other prevention options

Novartis changes executive committee

Robert Welteverden is appointed head of Novartis Business Services

Global mHealth market predicted to reach $58.8bn by 2020

And digital therapeutics could rival mainstream pharmaceutical products, according to a report

- PMLiVE

Real-world data finds patients feel better on Entresto, says Novartis

Patients on Entresto reported an “early, statistically significant improvement in health status”

- PMLiVE

Novartis, Amgen set low price for first CGRP migraine drug

Aimovig has a list price of $6,900 per year

- PMLiVE

Novartis legal head resigns over Cohen payments

General counsel steps down, but Novartis still facing difficult questions

- PMLiVE

AZ’s Fasenra hit by COPD trial failure

Results give advantage to respiratory rivals GSK

- PMLiVE

Daily Brief

A rapid round-up of the top pharma, biotech and healthcare news

- PMLiVE

Novartis launches remote clinical trial app

FocalView will allow patients to participate in ophthalmology trials

- PMLiVE

GSK gets maintenance indication for Trelegy

Will now treat airflow obstruction in COPD patients

- PMLiVE

Amgen and Novartis migraine drug hits the mark again

Aimovig will become the first CGRP receptor-targeting drug if it reaches market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links